Table 4 Comparison of complications between the PF-ILD and non-PF-ILD groups among patients with fibrosing ILD
From: Progressive fibrosing interstitial lung disease: prevalence and clinical outcome
Total | PF-ILD | Non-PF-ILD | P-value | |
|---|---|---|---|---|
Number of patients | 396 | 135 | 261 | |
Follow-up duration, months | 68.9 ± 32.5 | 59.9 ± 28.4 | 73.5 ± 33.5 | < 0.001 |
Unexpected respiratory hospitalisation | 120 (30.3) | 62 (45.9) | 58 (22.2) | < 0.001 |
Acute exacerbationa | 74 (18.7) | 38 (28.1) | 36 (13.8) | 0.001 |
Time interval from diagnosis (months) | 34.6 ± 28.2 | 29.3 ± 20.5 | 40.2 ± 33.9 | 0.037 |
Pneumonia | 35 (8.8) | 16 (11.9) | 19 (7.3) | 0.138 |
Pneumothorax | 7 (1.8) | 5 (3.7) | 2 (0.8) | 0.048 |
Pulmonary hypertension | 89 (22.5) | 45 (33.3) | 44 (16.9) | < 0.001 |
Lung cancer | 28 (7.1) | 14 (10.4) | 14 (5.4) | 0.065 |